{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T00:36:50Z","timestamp":1746319010349},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"Assistance Publique - H\u00f4pitaux de Marseille"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12885-016-2705-3","type":"journal-article","created":{"date-parts":[[2016,8,24]],"date-time":"2016-08-24T13:04:40Z","timestamp":1472043880000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Auto-immune thyroid dysfunction induced by tyrosine kinase inhibitors in a patient with recurrent chordoma"],"prefix":"10.1186","volume":"16","author":[{"given":"Juliette","family":"Eroukhmanoff","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederic","family":"Castinetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Penel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastien","family":"Salas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,8,24]]},"reference":[{"issue":"9","key":"2705_CR1","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1089\/thy.2010.0070","volume":"20","author":"M Iavarone","year":"2010","unstructured":"Iavarone M, Perrino M, Vigano M, Beck-Peccoz P, Fugazzola L. Sorafenib-induced destructive thyroiditis. Thyroid. 2010;20(9):1043\u20134.","journal-title":"Thyroid"},{"issue":"2","key":"2705_CR2","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1089\/thy.2010.0234","volume":"21","author":"L Doorn van","year":"2011","unstructured":"van Doorn L, Eskens FA, Visser TJ, van der Lugt A, Mathijssen RH, Peeters RP. Sorafenib induced thyroiditis in two patients with hepatocellular carcinoma. Thyroid. 2011;21(2):197\u2013202.","journal-title":"Thyroid"},{"issue":"4","key":"2705_CR3","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/j.1365-2265.2008.03253.x","volume":"69","author":"M Grossmann","year":"2008","unstructured":"Grossmann M, Premaratne E, Desai J, Davis ID. Thyrotoxicosis during sunitinib treatment for renal cell carcinoma. Clin Endocrinol (Oxf). 2008;69(4):669\u201372.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"2705_CR4","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/annonc\/mdm483","volume":"19","author":"I Tamaskar","year":"2008","unstructured":"Tamaskar I, Bukowski R, Elson P, Ioachimescu AG, Wood L, Dreicer R, Mekhail T, Garcia J, Rini BI. Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib. Ann Oncol. 2008;19(2):265\u20138.","journal-title":"Ann Oncol"},{"issue":"5","key":"2705_CR5","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.urolonc.2009.08.011","volume":"28","author":"H Miyake","year":"2010","unstructured":"Miyake H, Kurahashi T, Yamanaka K, Kondo Y, Muramaki M, Takenaka A, Inoue TA, Fujisawa M. Abnormalities of thyroid function in Japanese patients with metastatic renal cell carcinoma treated with sorafenib: a prospective evaluation. Urol Oncol. 2010;28(5):515\u20139.","journal-title":"Urol Oncol"},{"issue":"3","key":"2705_CR6","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1007\/s12020-012-9683-2","volume":"42","author":"C Konca Degertekin","year":"2012","unstructured":"Konca Degertekin C, Coskun U, Balos Toruner F, Akturk M, Demirci U. Hyperthyroidism and thyroid autoimmunity induced by sorafenib in metastatic renal cell cancer. Endocrine. 2012;42(3):756\u20137.","journal-title":"Endocrine"},{"issue":"11","key":"2705_CR7","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1089\/thy.2010.0251","volume":"20","author":"TD Kim","year":"2010","unstructured":"Kim TD, Schwarz M, Nogai H, Grille P, Westermann J, Plockinger U, Braun D, Schweizer U, Arnold R, Dorken B, et al. Thyroid dysfunction caused by second-generation tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia. Thyroid. 2010;20(11):1209\u201314.","journal-title":"Thyroid"},{"issue":"4","key":"2705_CR8","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.clpt.2005.06.010","volume":"78","author":"JW Groot de","year":"2005","unstructured":"de Groot JW, Zonnenberg BA, Plukker JT, van Der Graaf WT, Links TP. Imatinib induces hypothyroidism in patients receiving levothyroxine. Clin Pharmacol Ther. 2005;78(4):433\u20138.","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"2705_CR9","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1210\/jc.2007-0649","volume":"92","author":"JW Groot de","year":"2007","unstructured":"de Groot JW, Zonnenberg BA, van Ufford-Mannesse PQ, de Vries MM, Links TP, Lips CJ, Voest EE. A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma. J Clin Endocrinol Metab. 2007;92(9):3466\u20139.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2705_CR10","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1159\/000337086","volume":"58","author":"T Babacan","year":"2012","unstructured":"Babacan T, Sevinc A, Akarsu E, Balakan O. Sunitinib-induced autoimmune thyroiditis in a patient with metastatic renal cell carcinoma: a case report. Chemotherapy. 2012;58(2):142\u20135.","journal-title":"Chemotherapy"},{"issue":"9","key":"2705_CR11","doi-asserted-by":"crossref","first-page":"660","DOI":"10.7326\/0003-4819-145-9-200611070-00008","volume":"145","author":"J Desai","year":"2006","unstructured":"Desai J, Yassa L, Marqusee E, George S, Frates MC, Chen MH, Morgan JA, Dychter SS, Larsen PR, Demetri GD, et al. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med. 2006;145(9):660\u20134.","journal-title":"Ann Intern Med"},{"issue":"1","key":"2705_CR12","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/jnci\/djk008","volume":"99","author":"BI Rini","year":"2007","unstructured":"Rini BI, Tamaskar I, Shaheen P, Salas R, Garcia J, Wood L, Reddy S, Dreicer R, Bukowski RM. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst. 2007;99(1):81\u20133.","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"2705_CR13","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1210\/jc.2007-0586","volume":"92","author":"D Mannavola","year":"2007","unstructured":"Mannavola D, Coco P, Vannucchi G, Bertuelli R, Carletto M, Casali PG, Beck-Peccoz P, Fugazzola L. A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. J Clin Endocrinol Metab. 2007;92(9):3531\u20134.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2705_CR14","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1530\/EJE-08-0648","volume":"160","author":"F Illouz","year":"2009","unstructured":"Illouz F, Laboureau-Soares S, Dubois S, Rohmer V, Rodien P. Tyrosine kinase inhibitors and modifications of thyroid function tests: a review. Eur J Endocrinol. 2009;160(3):331\u20136.","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2705_CR15","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1089\/thy.2012.0378","volume":"23","author":"K Ohba","year":"2013","unstructured":"Ohba K, Takayama T, Matsunaga H, Matsushita A, Sasaki S, Oki Y, Ozono S, Nakamura H. Inappropriate elevation of serum thyrotropin levels in patients treated with axitinib. Thyroid. 2013;23(4):443\u20138.","journal-title":"Thyroid"},{"issue":"8","key":"2705_CR16","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/jjco\/hys076","volume":"42","author":"M Daimon","year":"2012","unstructured":"Daimon M, Kato T, Kaino W, Takase K, Karasawa S, Wada K, Kameda W, Susa S, Oizumi T, Tomita Y, et al. Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma. Jpn J Clin Oncol. 2012;42(8):742\u20137.","journal-title":"Jpn J Clin Oncol"},{"issue":"1","key":"2705_CR17","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1056\/NEJMoa075853","volume":"359","author":"SI Sherman","year":"2008","unstructured":"Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG, Licitra L, Eschenberg MJ, Sun YN, Juan T, et al. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med. 2008;359(1):31\u201342.","journal-title":"N Engl J Med"},{"issue":"9","key":"2705_CR18","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.molmed.2005.07.007","volume":"11","author":"M Mohty","year":"2005","unstructured":"Mohty M, Blaise D, Olive D, Gaugler B. Imatinib: the narrow line between immune tolerance and activation. Trends Mol Med. 2005;11(9):397\u2013402.","journal-title":"Trends Mol Med"},{"issue":"6","key":"2705_CR19","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1080\/14653240802317639","volume":"10","author":"R Seggewiss","year":"2008","unstructured":"Seggewiss R, Price DA, Purbhoo MA. Immunomodulatory effects of imatinib and second-generation tyrosine kinase inhibitors on T cells and dendritic cells: an update. Cytotherapy. 2008;10(6):633\u201341.","journal-title":"Cytotherapy"},{"issue":"4","key":"2705_CR20","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.molmed.2010.02.001","volume":"16","author":"B Seliger","year":"2010","unstructured":"Seliger B, Massa C, Rini B, Ko J, Finke J. Antitumour and immune-adjuvant activities of protein-tyrosine kinase inhibitors. Trends Mol Med. 2010;16(4):184\u201392.","journal-title":"Trends Mol Med"},{"key":"2705_CR21","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1089\/thy.2015.0170","volume":"25","author":"F Pani","year":"2015","unstructured":"Pani F, Atzori F, Baghino G, Boi F, Tanca L, Ionta MT, Mariotti S. Thyroid Dysfunction in Patients with Metastatic Carcinoma Treated with Sunitinib: Is Thyroid Autoimmunity Involved? Thyroid. 2015;25:11.","journal-title":"Thyroid"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-016-2705-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T21:18:06Z","timestamp":1498339086000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-016-2705-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,24]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["2705"],"URL":"https:\/\/doi.org\/10.1186\/s12885-016-2705-3","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,24]]},"article-number":"679"}}